RPDC concept

Concept for routine practice data collection – Odronextamab (relapsed or refractory follicular lymphoma)

Report documents

2025-03-06 A G-BA decision was published.

Project no.: A24-17
Commission: Commission awarded on 01.02.2024 by the Federal Joint Committee (GBA).
Report type: RPDC concept
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: Routine practice data collection (RPDC concept):
In the case of new drugs that have entered the health care system via a special marketing authorization or as a drug for the treatment of a rare disease, the study data at the time of marketing authorization are usually not very informative for the early benefit assessment. In these cases, according to the Law for More Safety in the Supply of Medicines (GSAV), the GBA can require the pharmaceutical company to collect routine practice data, including the associated analysis, for the benefit assessment. IQWiG prepares the concept for such a routine practice data collection on behalf of the GBA.
DOI: https://dx.doi.org/10.60584/A24-17

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.